ProSomnus (NASDAQ:OSA – Get Free Report) is one of 143 publicly-traded companies in the “Medical Devices” industry, but how does it contrast to its peers? We will compare ProSomnus to similar companies based on the strength of its profitability, dividends, risk, valuation, earnings, institutional ownership and analyst recommendations.
Profitability
This table compares ProSomnus and its peers’ net margins, return on equity and return on assets.
Net Margins | Return on Equity | Return on Assets | |
ProSomnus | -87.14% | N/A | -106.30% |
ProSomnus Competitors | -79.10% | -63.90% | -21.64% |
Volatility & Risk
ProSomnus has a beta of 0.21, suggesting that its stock price is 79% less volatile than the S&P 500. Comparatively, ProSomnus’ peers have a beta of 0.86, suggesting that their average stock price is 14% less volatile than the S&P 500.
Analyst Ratings
Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
ProSomnus | 0 | 1 | 3 | 0 | 2.75 |
ProSomnus Competitors | 308 | 1137 | 1352 | 40 | 2.40 |
ProSomnus currently has a consensus price target of $2.33, suggesting a potential upside of 345.38%. As a group, “Medical Devices” companies have a potential upside of 47.78%. Given ProSomnus’ stronger consensus rating and higher probable upside, equities research analysts clearly believe ProSomnus is more favorable than its peers.
Insider & Institutional Ownership
70.0% of ProSomnus shares are held by institutional investors. Comparatively, 26.4% of shares of all “Medical Devices” companies are held by institutional investors. 7.7% of ProSomnus shares are held by company insiders. Comparatively, 24.2% of shares of all “Medical Devices” companies are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
Earnings & Valuation
This table compares ProSomnus and its peers revenue, earnings per share and valuation.
Gross Revenue | Net Income | Price/Earnings Ratio | |
ProSomnus | $27.65 million | -$24.09 million | -0.34 |
ProSomnus Competitors | $471.36 million | $14.70 million | 90.69 |
ProSomnus’ peers have higher revenue and earnings than ProSomnus. ProSomnus is trading at a lower price-to-earnings ratio than its peers, indicating that it is currently more affordable than other companies in its industry.
Summary
ProSomnus peers beat ProSomnus on 8 of the 13 factors compared.
ProSomnus Company Profile
ProSomnus, Inc. operates as a medical technology company that develops, manufactures, and markets precision intraoral medical devices for treating and managing patients with obstructive sleep apnea. The company sells its products to sleep dentists, sleep physicians, primary care providers, otolaryngologists, and other integrated healthcare service providers through a direct sales force. ProSomnus, Inc. is headquartered in Pleasanton, California.
Receive News & Ratings for ProSomnus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ProSomnus and related companies with MarketBeat.com's FREE daily email newsletter.